Ionis Pharmaceuticals (IONS) Projected to Post Quarterly Earnings on Wednesday

Ionis Pharmaceuticals (NASDAQ:IONS) is expected to be issuing its quarterly earnings data before the market opens on Wednesday, February 19th. Analysts expect the company to announce earnings of ($1.09) per share and revenue of $140.97 million for the quarter. Parties that are interested in registering for the company’s conference call can do so using this link.

Ionis Pharmaceuticals Trading Up 2.3 %

Shares of IONS stock opened at $31.04 on Tuesday. Ionis Pharmaceuticals has a 1 year low of $30.23 and a 1 year high of $52.34. The company has a debt-to-equity ratio of 1.86, a current ratio of 8.91 and a quick ratio of 8.82. The stock’s 50 day simple moving average is $34.07 and its two-hundred day simple moving average is $38.67. The company has a market cap of $4.90 billion, a PE ratio of -12.72 and a beta of 0.34.

Wall Street Analysts Forecast Growth

IONS has been the topic of a number of recent research reports. Wells Fargo & Company decreased their price objective on Ionis Pharmaceuticals from $82.00 to $77.00 and set an “overweight” rating on the stock in a research report on Thursday, November 7th. StockNews.com downgraded Ionis Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, November 12th. Needham & Company LLC reiterated a “buy” rating and issued a $60.00 price target on shares of Ionis Pharmaceuticals in a report on Friday, December 20th. William Blair reiterated an “outperform” rating on shares of Ionis Pharmaceuticals in a report on Friday, December 20th. Finally, Piper Sandler reduced their price target on Ionis Pharmaceuticals from $65.00 to $62.00 and set an “overweight” rating on the stock in a report on Thursday, November 14th. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $60.65.

Insider Buying and Selling at Ionis Pharmaceuticals

In other news, Director Michael R. Hayden purchased 5,000 shares of the stock in a transaction on Monday, December 23rd. The stock was bought at an average price of $36.22 per share, with a total value of $181,100.00. Following the transaction, the director now owns 35,219 shares in the company, valued at $1,275,632.18. The trade was a 16.55 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Eric Swayze sold 7,154 shares of Ionis Pharmaceuticals stock in a transaction dated Thursday, January 16th. The stock was sold at an average price of $32.84, for a total value of $234,937.36. Following the sale, the executive vice president now directly owns 45,670 shares of the company’s stock, valued at approximately $1,499,802.80. This represents a 13.54 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 110,609 shares of company stock valued at $3,564,867. 2.71% of the stock is currently owned by corporate insiders.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.